BRAF and renal carcinoma: The present studies were initially conducted to determine whether the drug combination of [pazopanib + AR42], previously shown to kill sarcoma and renal carcinoma cells and now the subject of a phase I trial, could also kill melanoma cells expressing a mutated active B-RAF protein.